PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) is reporting second quarter financial results on Tuesday 13th August 2019, after market close.
According to analysts surveyed by Thomson Reuters, PHAS is expected to report 2Q19 loss of $ 0.32 per share from revenue of $ 0.16 million.
For the full year, analysts anticipate top line of $ 1.01 million, while looking forward to loss of $ 1.32 per share bottom line.
Historical Earnings Performance
3Q18 results surrendered to wall street expectation by 2 percent, the report represented loss of $ 10.45 per share, analysts expected loss of $ 0.48 per share
4Q18 results topped market view by 13.33 percent, the report depicted loss of $ 0.26 per share from the topline of $ 0.41 million, analysts forecasted loss of $ 0.3 per share
1Q19 results exceeded market expectation by 26.83 percent, the report outlined loss of $ 0.3 per share from the reveues of $ 0.26 million, analysts predicted loss of $ 0.41 per share